[go: up one dir, main page]

KR930012023A - 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 - Google Patents

환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 Download PDF

Info

Publication number
KR930012023A
KR930012023A KR1019920023909A KR920023909A KR930012023A KR 930012023 A KR930012023 A KR 930012023A KR 1019920023909 A KR1019920023909 A KR 1019920023909A KR 920023909 A KR920023909 A KR 920023909A KR 930012023 A KR930012023 A KR 930012023A
Authority
KR
South Korea
Prior art keywords
dextran
recombinant human
composition
reduced form
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019920023909A
Other languages
English (en)
Inventor
로우셀-우크라프
Original Assignee
장-끌로드 비에이으포스
로우셀-우크라프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장-끌로드 비에이으포스, 로우셀-우크라프 filed Critical 장-끌로드 비에이으포스
Publication of KR930012023A publication Critical patent/KR930012023A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

본 발명은 개선된 안정성을 갖는 환원된 형태, 특히 동결건조된 형태의 비글리코실화 재조합 인체 IL2의 제약 조성물 및 의약으로서의 그의 용도에 관한 것이다.

Description

환원된 형태의 비글리코실화 재조합 인체 IL2의 안정화된 제약 조성물 및 그이 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 시트르산 및 만리톨을 함유하고, 덱스트란 및 EDTA 칼슘염을 함유하는 것을 특징으로 하는, 환원된 형태의 비글리코실화 재조합 인체 IL2의 안정화된 제약 조성물.
  2. 제1항에 있어서, 덱스트란의 평균 분자량이 약 40,000 내지 110,000 임을 특징으로 하는 조성물.
  3. 제2항에 있어서, 덱스트란의 평균 분자량이 약 70,000 임을 특징으로 하는 조성물.
  4. 제3항에 있어서, 덱스트란 : IL2의 중량비가 약 20 내지 약 80 임을 특징으로 하는 조성물.
  5. 제4항에 있어서, 덱스트란 : IL2의 중량비가 약 40 임을 특징으로 하는 조성물.
  6. 제5항에 있어서, IL2 : 시트르산 : 만니톨 : 텍스트란 : EDTA 칼슘염의 중량비가 약 1 : 10 : 50 : 40 : 0.01임을 특징으로 하는 조성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 필수적으로 IL2 이량체가 없음을 특징으로 하는 조성물.
  8. 덱스트란, EDTA 칼슘염 및 만니틀을 함유하는 용액을 시트르산을 함유하는 IL2의 수용액에 첨가하여 용액을 동결건조시킴을 특징으로 하는, 환원된 형태의 비글리코실화 재조합 인체 IL2의 안정화된 동결건조된 제약 조성물의 제조 방법.
  9. 시트르산 및 만니톨을 함유하는 환원된 형태의 비글리코실화 재조합 인체 IL2의 제약 조성물을 안정화시키기 위한 덱스트란 및 EDTA칼슘염의 용도.
  10. 덱스트란 및 EDTA칼슘염을 첨가함을 특징으로 하는 스트르산 및 만니톨을 함유하는 환원된 형태의 비글리코실화 재조합 인체 IL2의 제약 조성물의 안정화 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920023909A 1991-12-12 1992-12-11 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 Ceased KR930012023A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR91-15418 1991-12-12
FR9115418A FR2684878B1 (fr) 1991-12-12 1991-12-12 Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Publications (1)

Publication Number Publication Date
KR930012023A true KR930012023A (ko) 1993-07-20

Family

ID=9419958

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920023909A Ceased KR930012023A (ko) 1991-12-12 1992-12-11 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법

Country Status (18)

Country Link
US (1) US5340574A (ko)
EP (1) EP0554634B1 (ko)
JP (1) JP3291340B2 (ko)
KR (1) KR930012023A (ko)
AT (1) ATE135917T1 (ko)
AU (1) AU662940B2 (ko)
CA (1) CA2085142A1 (ko)
DE (1) DE69209486T2 (ko)
DK (1) DK0554634T3 (ko)
ES (1) ES2084965T3 (ko)
FR (1) FR2684878B1 (ko)
GR (1) GR3019440T3 (ko)
HU (1) HU218103B (ko)
IL (1) IL103862A (ko)
MX (1) MX9207199A (ko)
RU (1) RU2107511C1 (ko)
UA (1) UA26898C2 (ko)
ZA (1) ZA929627B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018119A1 (fr) * 1997-10-03 1999-04-15 Shionogi & Co., Ltd. Procede de lyophilisation de proteines
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
RU2169004C1 (ru) * 1999-11-23 2001-06-20 Государственный научно-исследовательский институт особо чистых биопрепаратов Ранозаживляющая композиция
PT1599222E (pt) 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
WO2006131515A2 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised il-21 compositions
MY160916A (en) * 2010-04-27 2017-03-31 Scil Tech Gmbh Stable mia/cd-rap formulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251001C (ko) *
FR353150A (fr) * 1905-04-08 1905-09-04 Gerardo Caffaro Compteurs à gaz
FR452598A (fr) * 1912-12-26 1913-05-19 Lanston Monotype Corp Ltd Perfectionnements apportés aux machines servant à la composition typographique
DE3575072D1 (de) * 1984-03-28 1990-02-08 Cetus Corp Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2.
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5204094A (en) * 1991-01-17 1993-04-20 Roussel Uclaf Treatment of pneumothorax

Also Published As

Publication number Publication date
FR2684878B1 (fr) 1994-02-11
JPH05345728A (ja) 1993-12-27
DE69209486D1 (de) 1996-05-02
EP0554634B1 (fr) 1996-03-27
CA2085142A1 (fr) 1993-06-13
EP0554634A1 (fr) 1993-08-11
ATE135917T1 (de) 1996-04-15
IL103862A (en) 1997-02-18
FR2684878A1 (fr) 1993-06-18
AU662940B2 (en) 1995-09-21
JP3291340B2 (ja) 2002-06-10
RU2107511C1 (ru) 1998-03-27
DK0554634T3 (da) 1996-07-01
ZA929627B (en) 1993-12-13
AU3004192A (en) 1993-06-17
US5340574A (en) 1994-08-23
IL103862A0 (en) 1993-04-04
DE69209486T2 (de) 1996-09-12
UA26898C2 (uk) 1999-12-29
GR3019440T3 (en) 1996-06-30
MX9207199A (es) 1993-07-01
HUT63575A (en) 1993-09-28
HU9203925D0 (en) 1993-03-29
HU218103B (hu) 2000-06-28
ES2084965T3 (es) 1996-05-16

Similar Documents

Publication Publication Date Title
KR890003400A (ko) 경비(經鼻)투여용 생리 활성 펩티드 분말 조성물(제제)
DK0674510T3 (da) Injicerbart præparat omfattende paclitaxel
DK524187D0 (da) Aminosyrechelaterede midler til udlevering til specifikke biologiske vaevssteder
KR920019371A (ko) 안정화된 인자 ⅷ 제제
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
DK0494391T3 (da) Kosmetisk middel med to faser
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
KR940703689A (ko) 성장호르몬과 아스파라진으로 이루어지는 안정화된 약학제제(a stabil-ized pharmaceutical formulation comprising growth gormone and asparagine)
BR9714434A (pt) Formulações de interferon liquidas estáveis
JP2005527470A5 (ko)
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
DE3770280D1 (de) Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha.
SE8802569L (sv) Foerbaettringar vid eller avseende somatosstatiner
SE8901041L (sv) Antitrombotiska farmaceutiska preparat samt foerfarande foer deras framstaellning
SE9101155D0 (sv) Novel heparin derivatives
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
JPS6416724A (en) Stable and injectable vinca dimer salt solution
KR880008801A (ko) 비경구 투여용 용액제
PH27567A (en) Topical compositions
HUP9904327A2 (hu) Kinupristint és dalfopristint tartalmazó gyógyszerkészítmények és eljárás előállításukra
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19921211

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19971211

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19921211

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991030

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991030

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I